Home/Pipeline/DSP-6745

DSP-6745

Treatment-Resistant Depression

Phase 1Active

Key Facts

Indication

Treatment-Resistant Depression

Phase

Phase 1

Status

Active

Company

Sumitomo Pharma

About Sumitomo Pharma

Sumitomo Pharma is a research-driven pharmaceutical company with a mission to deliver innovative therapeutic solutions for serious unmet medical needs. Its strategic direction is built on a foundation of internal R&D and strategic acquisitions, such as the merger with Myovant Sciences and the acquisition of Tolero Pharmaceuticals, to bolster its pipeline in key therapeutic areas. The company faces challenges from patent expirations but is actively investing in next-generation modalities like cell and gene therapies to drive future growth.

View full company profile

Therapeutic Areas

Psychiatry & Neurology Oncology Women's Health Regenerative Medicine

Other Treatment-Resistant Depression Drugs

Drug	Company	Phase	Status
JNJ-1802	Johnson & Johnson	Phase 2	Active
ML-104	MapLight Therapeutics	Preclinical	Lead optimization
PSG-301	PharmaSGP	Preclinical	Active